Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well known as a novel member of the coronavirus family which caused a sudden outbreak of Coronavirus disease 2019 (COVID-19) in Wuhan, China that quickly developed into a global pandemic. No effective approaches are found as yet for the therapy and epidemiological control of this new virus. For this purpose, we searched the literature in PubMed, Scopus, Web of Knowledge, Google Scholar, and MeSH, from all years of study until 23rd of October 2020, for articles and abstracts describing SARS-CoV-2, COVID-19, pneumonia, clinical trials, drug, treatment, and medicine.
Areas covered: The present study aimed to comprehensively overview of the current literature on effective anti- SARS-CoV-2 drugs.
Expert opinion: Since the beginning of this pandemic disease, many studies have been conducted to find effective drugs to prevent COVID-19, because there are no specific drugs for the treatment of this disease. Most of these drugs with the antiviral potential effect toward COVID-19 are already used as the treatment of other infectious diseases. Some drugs that show the promising therapeutic potential in the initial clinical studies include remdesivir as an inhibitor of RNA-dependent RNA polymerase and favipiravir as an inhibitor of virus replication. Currently, remdesivir received the FDA authorizes to use as an experimental drug for emergency use in COVID-19 patients.
Keywords: COVID-19; Clinical trials; Drug; Pneumonia; SARS-CoV-2.